Background Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1-3 inhibitor that has shown antitumour activity in recurrent ovarian cancer. We assessed effi cacy and safety of cediranib in combination with platinum-based chemotherapy and as continued maintenance treatment in patients with fi rst relapse of platinum-sensitive ovarian cancer.
Introduction
Ovarian cancer, the leading cause of death from gynaecological tumours in high-income countries, initially responds well to surgery and platinum-based chemotherapy. Most patients develop recurrent treatable disease, albeit with diminishing benefi t from each subsequent regimen. 1 Although the cumulative eff ect of successive lines of chemotherapy might be to extend survival, the duration of response shortens with each line of therapy, and the potential to increase the interval between treatments by using maintenance treatment to delay the need for further chemotherapy is deemed a clinically valuable research objective and benefi cial for patients. One way of achieving this goal is to inhibit angiogenesis, the process of new blood vessel formation, which is needed for tumour growth. 2 This approach has been validated through phase 3 trials with the monoclonal antibody to vascular endothelial growth factor (VEGF), bevacizumab, which increases the response rate to chemotherapy [3] [4] [5] and extends progression-free survival. [3] [4] [5] [6] Cediranib is an oral VEGF receptor (VEGFR 1-3) and c-Kit 7 inhibitor that has shown antitumour activity in recurrent ovarian, colorectal, advanced biliary tract, renal, and lung cancers, and glioblastoma and alveolar soft-part sarcoma. [8] [9] [10] [11] [12] [13] [14] On the basis of the phase 2 activity in ovarian cancer, 8 we investigated the effi cacy and safety obtained by giving cediranib with chemotherapy and as maintenance treatment in patients with platinumsensitive 15 ovarian cancer who had radiological evidence of recurrence more than 6 months after completion of fi rst-line chemotherapy. The International Collaboration for Ovarian Neoplasia 6 (ICON6) trial was an investigatorinitiated, academically led trial developed through the Gynecologic Cancer InterGroup, and led by the Medical Research Council Clinical Trials Unit at University College London in the UK.
Methods

Study design and participants
We did an international, three-arm, randomised, doubleblind, placebo-controlled, phase 3 trial of cediranib in patients with relapsed platinum-sensitive ovarian cancer in 63 centres in Australia, Canada, New Zealand, Spain, and the UK. Participants were at least 18 years old and had CT or MRI evidence of recurrent ovarian, fallopian tube, or primary peritoneal cancer requiring further platinum-based chemotherapy at least 6 months after completing fi rst-line chemotherapy. Patients had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 but were ineligible if they had poorly controlled hypertension, arterial thrombotic events within 12 months, substantial haemorrhage, or major surgery in the preceding 2 weeks before the start of treatment. Following ethical approval all patients provided written informed consent. The study protocol is available online.
Randomisation and masking
Patients were randomly assigned (2:3:3) to three parallel treatment arms: in arm A (reference) patients received platinum-based chemotherapy plus once-daily oral placebo tablets during the chemotherapy phase, then received placebo alone during the maintenance phase; in arm B (concurrent), patients received platinum-based chemotherapy plus once-daily oral cediranib, then switched to placebo during the maintenance phase; in arm C (concurrent plus maintenance), patients received once-daily oral cediranib during both phases.
Research in context
Evidence before this study In 2003, we published the results of the International Collaborative for Ovarian Neoplasia (ICON) 4 trial in The Lancet, showing the value of platinum-combination treatment for women relapsing more than 6 months after completing fi rstline treatment for ovarian cancer. This set a new standard of care with an improvement in overall survival, but the benefi t was slight. In around 2006, unpublished data began to emerge showing that inhibitors of angiogenesis, blocking either the vascular endothelial growth factor (VEGF) ligand or its receptor could lead to shrinkage of ovarian tumours and delayed disease progression. We designed a three-arm, placebo-controlled, randomised trial (ICON6) in collaboration with the Gynaecological Cancer InterGroup adding the VEGF receptor tyrosine kinase inhibitor cediranib to chemotherapy and then continued as maintenance treatment. No previous trials of maintenance treatment with a molecularly targeted treatment in ovarian cancer had been done, although during this time, trials with the monoclonal antibody bevacizumab were in development for fi rst-line treatment and for women with fi rst relapse. ICON6 was an academic-led trial and complemented AstraZeneca-sponsored or supported studies with cediranib (as cediranib was only available through the company) in lung and colon cancer and in glioblastoma.
Added value of this study
In ICON6 we have shown that the addition of cediranib to platinum-based chemotherapy prolongs the progression-free survival of women with ovarian cancer. The three-arm trial shows an eff ect of maintenance cediranib over and above the eff ect of adding it to chemotherapy. The magnitude of benefi t was similar to a trial with bevacizumab in a similar group of patients. Survival data are immature, but ICON6 is the fi rst trial to show the benefi t of a VEGF receptor tyrosine kinase inhibitor in recurrent ovarian cancer. Toxic eff ects, particularly diarrhoea, fatigue, and hypertension, are problematic in some patients, and a proportion of the patients stopped the trial early because of side-eff ects. However, the results of cediranib and bevacizumab trials show that antiangiogenic treatment is a new treatment option for women with relapsed ovarian cancer, and cediranib is the fi rst oral drug to be benefi cial in this setting.
Implications of all the available evidence
Development of treatments to prolong disease control of ovarian cancer is a key therapeutic aim. Trials of cediranib in other tumour types showed no evidence of a benefi t, but the positive results in ICON6 have led the manufacturer to re-start development of cediranib in ovarian cancer. Another trial in the USA has shown that the addition of cediranib to the PARP inhibitor olaparib improves progression-free survival in a similar group of patients, further extending the potential of cediranib in this disease. The results of ICON6 have been shared with AstraZeneca who have now applied to the European Medicines Agency for market authorisation. A successful application will provide women with a new therapeutic option for recurrent ovarian cancer.
For more on the study protocol see http://www.icon6.org/ protocol/ Randomisation was done centrally by a third party via an interactive voice and web response system. Permuted blocks were used (alternating between eight and 16) stratifi ed by Gynecologic Cancer InterGroup, fi rst-line chemotherapy (paclitaxel or other), relapse-free interval (6-12 months vs >12 months), planned chemotherapy regimen, and previous bevacizumab treatment. Both patients and the treating clinician were masked to the assigned treatment. Before the start of the trial, the Clinical Trials Unit tested samples of cediranib and matched placebo for eff ectiveness of match with a panel of fi ve testers. Samples were examined for colour, shape/ consistency, smell, and taste. No signifi cant diff erences were detected in any of the four features or overall between the cediranib and matched placebo
Procedures
Six cycles of chemotherapy (once every 3 weeks) were planned, but patients unable to complete six cycles and who were responding to treatment could begin maintenance treatment after at least four cycles were completed. Maintenance treatment for 18 months from initiation of all treatment for relapse was originally planned; however, a protocol modifi cation in February, 2010, allowed patients to continue masked treatment beyond 18 months to progression if they were thought to be still deriving clinical benefi t by the treating clinician. Recommended chemotherapy was carboplatin with either paclitaxel or gemcitabine. Carboplatin monotherapy was permitted, as was cisplatin, if carboplatin could not be given. 16, 17 Protocol-defi ned dose reductions of chemotherapy were done if necessary.
The trial drug, cediranib or placebo, was started with chemotherapy and continued to progression or excessive toxic eff ects. An initial safety phase used a single daily dose of 30 mg. After review of the fi rst 30 patients in November, 2008, 18 the Independent Data Monitoring Committee recommended reduction of the dose of cediranib to 20 mg, in line with ongoing combination phase 3 trials in lung cancer, colorectal cancer, and glioblastoma, 9, 19, 20 and continuation of the trial. Clinicians were provided with clinical management guidelines to help early management of the main toxic eff ects of cediranib, which are hypertension, diarrhoea, proteinuria, and fatigue. Interruption of trial drug for up to 2 weeks as a result of toxic eff ects was permitted to allow recovery to grade 1 or less. A dose reduction to 15 mg was permitted, and needed for toxic eff ects of grade 3 or more. Cediranib or placebo was discontinued permanently if gastrointestinal perforation, arterial thromboembolic events, grade 4 haemorrhage, hypertensive crisis, or reversible posterior leuko encephalopathy syndrome occurred.
Baseline measurable disease was not needed. Tumour assessments were done by CT or MRI before treatment, at chemotherapy completion (week 18), and thereafter at weeks 52, 78, and when clinically needed. Patients were reviewed before each chemotherapy cycle and every 6 weeks during maintenance treatment. Increasing CA-125 concentrations alone did not defi ne progression, but could trigger unscheduled CT or MRI assessment to detect progression at any time (for full defi nition of investigator-declared progression see appendix). Patients were not unmasked on progression.
Outcomes
ICON6 was originally planned with three stages: safety, effi cacy with a progression-free survival outcome using RECIST criteria, 21 and a third expanded phase with overall survival as the primary outcome. We had to redesign the trial towards the end of the second phase because continuation to the third phase was not possible when AstraZeneca discontinued cediranib development in October, 2011, after disappointing outcomes in pivotal trials of other cancer types. 9, 12 The prospective analysis plan was modifi ed (with no outcome analysis done) to account for shortage in future drug supply. The primary outcome changed to a progression-free survival comparison between arms A and C, which was deemed most clinically relevant in view of emerging data for maintenance bevacizumab 3, 4, 6 . Progression-free survival was defi ned as time from randomisation to disease progression or death from any cause (appendix). 3, 4, 6 Overall survival and comparison of progression-free survival in all three arms became secondary endpoints, along with assessment of toxicity and quality of life. The timeline for key milestones in the trial procedure, including the redesign, are outlined in the appendix. Toxicity was assessed locally by investigators and all adverse events were reported.
Statistical analysis
After protocol amendment to the primary endpoint, the revised sample size needed 440 patients randomly assigned to receive cediranib 20 mg, excluding those who received 30 mg (see appendix for analysis of these patients). 176 events in arms A and C would provide at least 80% power to detect a progression-free survival hazard ratio (HR) of 0·65 with a 5% two-sided signifi cance level. In October, 2012, the target number of events was imminent, but the statistical analysis plan was revised (with no outcome analysis having been done) because a substantial proportion of patients in arms B and C who were receiving treatment had not yet reached 18 months of treatment. As the primary analysis was between no cediranib (arm A) and a planned 18 months of cediranib (arm C), we deemed it wise to delay the analysis by a few months until an estimated 5% or less of patients were on cediranib or placebo.
Analyses were done on an intention-to-treat basis. Patients were censored at date of last follow-up if they had not progressed or died by the time of analysis. For the overall survival analysis, which included death from any cause, the date of censoring was brought forward to the data cutoff date for any patients who were confi rmed to have been alive at a later date (appendix). Preliminary results were presented in 2013; 22 the results presented here follow subsequent extensive data cleaning, although diff erences are slight and detailed in the appendix. Other sensitivity analyses are also described (appendix).
The log-rank test was used as the primary test of an overall diff erence between Kaplan-Meier curves for both progression-free survival and overall survival. A prespecifi ed plan to address the proportionality of hazards was made because of the diffi culty of interpreting the HR in the presence of time-dependent treatment eff ects. The presence of non-proportional hazards was assessed with the Grambsch-Therneau test. 23 With evidence of non-proportionality at the 5% level, survival data would be modelled by a fl exible parametric model (3 degrees of freedom for the baseline hazard function, 1 degree of freedom for the timedependent treatment eff ect) and diff erences in restricted mean survival time would be estimated. 24 
Role of the funding source
The funders of the study had no role in the study design, data collection (except for the collection of images for masked central imaging review), data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Recruitment of patients to ICON6 took place between Nov 13, 2007, and Dec 23, 2011, at 63 centres in the UK, Canada, Australia, New Zealand, and Spain. 486 patients were randomly assigned; however, the results presented here are for the 456 patients randomly assigned after the cediranib dose was reduced to 20 mg per day in November, 2008 (30 patients were randomly assigned to receive 30 mg cediranib, but then the trial was restarted at 20 mg because of toxicity and to bring it inline with other cediranib trials; fi gure 1). Baseline characteristics were well balanced between groups (table 1). 22 (5%) patients had a second debulking attempt that was done before randomisation. No patients were lost to follow-up and fi ve withdrew consent for collection of further data (one patient in arm A, one in arm B, and three in arm C). Median follow-up was 19·5 months (IQR 14-26), during which 410 (90%) of the 456 patients had disease progression, including 113 (96%) of 118 patients in arm A, 156 (90%) of 174 patients in arm B, and 141 (86%) of 164 patients in arm C. Median progression-free survival was 11·0 months (95% CI 10·4-11·7) in arm C and 8·7 months (7·7-9·4) in arm A (HR 0·56, 0·44-0·72, p<0·0001). 156 (90%) of 174 patients in arm B had disease progression, and median progression-free survival was 9·9 months (9·4-10·5). Some evidence of non-proportional hazards was noted (p=0·06) and the restricted mean survival time over 2 years was 12·5 months (11·7-13·4) in arm C and 9·4 months (8·6-10·2) in arm A.
The diff erence between groups in progression-free survival was statistically signifi cant when arm B, concurrent cediranib, was included in the analysis (likelihood ratio p trend <0·0001). For this secondary analysis, the median progression-free survival was 9·9 months (9·4-10·5) and restricted mean survival time over 2 years was 11·0 months (10·4-11·5). Kaplan-Meier plots (fi gure 2) seem to suggest similar survival in arms B and C during the chemotherapy phase when both groups were receiving cediranib, then worsening survival in arm B after the switch to placebo.
Overall survival data are immature because only 236 (52%) of 456 of patients had died at data cutoff (fi gure 3). Median overall survival was 26·3 months (95% CI 23·8-30·0) in arm C and 21·0 months (17·7-27·6) in arm A (HR 0·77, 95% CI 0·55-1·07, p=0·11). We noted evidence of non-proportional hazards (p=0·001), and restricted mean survival time over 3 years was 25·7 months (24·3-27·2) in arm C and 22·8 months (20·7-24·8) in arm A (diff erence 3 months, 95% CI 0·3-5·7). The diff erence in overall survival was non-signifi cant (likelihood ratio trend p=0·3) across the three randomised arms, again with evidence of non-proportional hazards (p=0·005). An updated survival analysis with more mature data will be reported at a later stage.
About 80% of patients completed six cycles of chemotherapy in all arms (fi gure 1). Treatment was not started in 12 patients (three in arm A, three in arm B, and six in arm C) who were thus excluded from the safety analysis. 149 (33%) of 456 patients discontinued treatment with cediranib or placebo early, before progressive disease or death occurred. Discontinuation before progression was more common with cediranib than placebo, most frequently for adverse events (table 2) . Overall, drug discontinuation was high in all three arms excluding stopping due to progression or death (19 [17%] of 115 patients in arm A, 64 [37%] of 171 in arm B, and 76 [48%] of 158 in arm C). These discontinuations were disproportionately higher in the two experimental arms despite provision of clinical guidelines for the management of cediranib toxic eff ects. Most discontinuations also occurred while patients were still receiving chemotherapy: 14 (74%) of the 19 discontinuations in arm A, 53 (83%) of the 64 in arm B, and 56 (74%) of the 76 in arm C. Median time receiving cediranib or placebo was 8·0 months (5·1-11·0) in arm A, 7·4 months (2·6-10·8) in arm B, and 7·5 months (2·5-11·9) in arm C, and at time of analysis, 5% of patients continued unblinded on trial treatment. No dose reductions of cediranib or placebo occurred in arm A, but 14 (8%) of 171 patients in arm B and 21 (13%) of 158 patients in arm A and C received a reduced drug dose.
Adverse events, reported with Common Terminology Criteria for Adverse Events, are described separately for the chemotherapy phase, and for the maintenance phase when patients received cediranib or placebo without other treatment (table 3) .
In line with previous early-phase studies of cediranib, 8, 9, 13, 19 we noted an increased incidence of diarrhoea, neutropenia, hypertension, and voice changes, but not fatigue, nausea, or anorexia during chemotherapy in arms B and C compared with arm A. During cediranib maintenance treatment, an increased incidence of diarrhoea, hypothyroidism, and voice changes occurred, but not of hypertension because this seemed to be controlled after prompt management in the early chemotherapy phase. Four (3%) of 115 patients in arm A and 38 (12%) of 329 patients in arms B and C had grade 3 or higher hypertension during chemotherapy, reducing to 8 (4%) of 198 patients in arms A and B and 5 (5%) of 95 patients in arm C during maintenance (table 3) . During chemotherapy, the most common adverse event was fatigue at any grade (412 [93%] of 444 patients), and diarrhoea at any grade was also common (350 [79%] of 444 patients; table 3). Toxic eff ects were reduced in the maintenance phase, with fatigue, diarrhoea, and nausea occurring most commonly. We noted diff erences between arms A and B and arm C with diarrhoea, voice changes, and haemorrhage. Reports of toxic eff ects in placebo treatment (arms A and B) were not uncommon.
A full analysis of quality-of-life data will be described elsewhere. The primary outcome compared global Chemotherapy delivery for all patients randomly assigned to the intention-to-treat analysis (n=456) and discontinuations of trial drug for patients included in the safety analysis (n=444). 2 patients in arm A, 7 in arm B, and 3 in arm C reported adverse events and disease progression as reasons for trial drug discontinuation, so for this table they were assigned as discontinuing because of toxic eff ects. quality of life at 12 months between arms A and C, measured by the Quality of Life Questionnaire-C30 and adjusted for baseline value. 235 patients were in follow-up at 12 months and had quality-of-life data at baseline and 12 months. Mean global quality of life was 4·5 points higher in arm C than in arm A, which is not a clinically or statistically signifi cant diff erence (p=0·2, although the 95% CI of -2·0 to 11·0 includes a moderate diff erence of 10 points). We recorded no signifi cant diff erence between groups in each of three secondary hypotheses (appendix).
There was also no signifi cant diff erence between groups in each of three secondary hypotheses.
Discussion
This phase 3 trial showed that the addition of cediranib to platinum-based chemotherapy followed by maintenance cediranib in patients with recurrent platinum-sensitive ovarian cancer was associated with prolonged progression-free survival compared with chemotherapy alone. Bevacizumab studies also suggest that the greatest benefi t of an antiangiogenic drug is achieved by adding it to chemotherapy and continuing the drug as a maintenance treatment. 3, 4, 6 We were able to distinguish these two components in ICON6 to show that the greatest benefi t was from concurrent plus maintenance treatment, whereas in the concurrent-only group, the early benefi t of addition of cediranib to chemotherapy seemed to dissipate as patients switched to placebo maintenance.
The 8·7 month median progression-free survival in the reference group of ICON6 is consistent with other trials 4, 17, 25 and the improvement in progression-free survival to a median of 11·0 months with maintenance cediranib is similar to that reported with bevacizumab maintenance after chemotherapy in a similar population. 4, 26 By comparison with intravenous bevacizumab, oral antiangiogenic drugs are easier to give, but have a diff erent toxic profi le of hypertension, fatigue, diarrhoea, and nausea. 27 Prompt management of toxic eff ects to restrict the number of patients needing a dose reduction or discontinuing cediranib is important and was helped by the inclusion of clinical management guidelines in ICON6. Planned chemotherapy cycles were not compromised by cediranib (80% of patients completing six cycles, consistent across groups); however, during the chemotherapy phase, 32% of patients in the two cediranib arms discontinued cediranib because of toxic eff ects compared with 10% of those receiving placebo. In the maintenance phase, 10% of patients discontinued cediranib because of toxic eff ects compared with 2% of those on placebo. Whether planned brief dose interruptions were suffi ciently used is hard to tell and should be investigated in further studies as a strategy for managing discontinuations. From experience, treatment interruptions and prompt dose reductions have proved to be successful in other widely used tyrosine kinase inhibitors. 28 The revised sample size, due to the shortage of cediranib supply, reduced the power to show a signifi cant diff erence in overall survival. A signifi cant Summary of adverse events as maximum grade reported by phase of trial in safety analysis patients (n=444). Groups are split into cediranib-containing and non-cediranib-containing arms according to the phase of the trial. Seven grade 5 serious adverse events occurred: pneumonia and somnolence in arm A; pneumonia, gastrointestinal perforation, and cardiac ischaemia in arm B; and pancreatitis and hypoxia in arm C. *Diarrhoea seems to be the only toxic eff ect that could have a carryover eff ect into the maintenance phase, with arm B having greater grade 1 and 2 levels than arm A. †No grade 4 or 5 hypertension (hypertensive crisis or death). survival diff erence has not been noted with any antiangiogenic drug trials in recurrent ovarian cancer. In ICON6, a 5·3 month diff erence in median overall survival was reported between reference and maintenance cediranib arms. With a 3-year restricted mean survival time analysis, the overall survival diff erence was 3 months. However, the ICON6 overall survival analysis was done when only 52% of expected deaths had occurred and it will be assessed again when more than 80% of deaths have occurred, although because of the small sample size, the power to detect a realistic diff erence will be restricted.
In absolute terms, survival in all groups was somewhat shorter than reported in other trials of combination therapy in recurrent ovarian cancer, with or without maintenance treatment. 4, 25 This probably refl ects diff erences between trial cohorts in timing of initiation of second-line treatment, because the median duration of survival as measured from the time of original diagnosis, 46 months with cediranib, compares favourably with other trials.
The improvement in time to progression seen with the combination of cediranib and chemotherapy, followed by maintenance cediranib, represents a clinically relevant prolongation in progression-free survival for patients with recurrent ovarian cancer and is in line with other VEGF maintenance trials. 4 Two other oral VEGFR inhibitors, pazopanib and nintedanib, 29, 30 have shown slight improvements in progression-free survival in fi rstline treatment of ovarian cancer. However, toxic eff ects of cediranib and other VEFR inhibitors can be problematic 29 and need careful management. The three-arm ICON6 trial has shown that the benefi t in progression-free survival with cediranib is derived from continuing cediranib as a maintenance treatment after chemotherapy. Cediranib is a new treatment option that should be considered for the treatment of patients with platinum-sensitive recurrent ovarian cancer.
